India's Pharmaceutical Industry: Growth and Regulatory Challenges

Introduction

India's pharmaceutical industry is the third-largest in the world by volume and the 11th largest by value. Known as the 'pharmacy of the world', India supplies over 60% of global vaccines, 25% of all generic medicines in the US, and meets 80% of Africa's generic drug demand. The industry is currently valued at approximately USD 50 billion with exports exceeding USD 25 billion annually.

Historical Evolution

• 1901–1947: Limited manufacturing; dominated by foreign multinationals
• 1950s–1970s: Public sector entry (HAL, Bengal Chemicals); focus on basic drugs
• 1970: Indian Patents Act — product patents abolished, only process patents allowed (enabled reverse engineering)
• 1971: Drug Price Control Order (DPCO) — price regulation of essential medicines
• 1990s: Liberalisation opened the sector; rapid growth of generics
• 2005: TRIPS compliance — product patents reintroduced; shift toward innovation
• 2020–present: Focus on API self-reliance, R&D, and biosimilars

Key Segments

Generics

• India's core strength; 70% of the market by value
• Abbreviated New Drug Applications (ANDA) filings: India is the largest filer in the US
• Companies: Sun Pharma, Dr Reddy's, Cipla, Aurobindo, Lupin

Active Pharmaceutical Ingredients (APIs)

• India accounts for ~18% of global API production by volume
• Heavy dependence on China (~65% of API imports)
• Critical vulnerability: China supplies key starting materials for antibiotics, vitamins, steroids
• PLI scheme aims to reduce import dependence

Biosimilars

• High-growth segment; India has approved over 100 biosimilars
• Strong capabilities in complex biologics and vaccines
• Serum Institute of India: World's largest vaccine manufacturer by volume

Vaccines

• India produces 60% of the world's vaccines
• Key players: Serum Institute, Bharat Biotech, Biological E
• Covaxin and Covishield production demonstrated pandemic manufacturing capability

Contract Research and Manufacturing Services (CRAMS)

• India is a preferred destination for R&D outsourcing
• Cost advantage: 30–40% lower than developed countries
• Clinical trial capabilities: Large, diverse patient population

Growth Drivers

• Cost advantage: 50–60% lower manufacturing costs than the US
• Skilled workforce: Large pool of scientists, chemists, and pharmacists